Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...
Metsera Announces Pricing of Initial Public Offering
A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...
Yahoo Finance8d
Metsera Announces Pricing of Initial Public Offering
In addition, Metsera has granted the underwriters a 30-day option to purchase up to an additional 2,291,666 shares of common stock at the initial public offering price less underwriting discounts ...
Nasdaq8d
Metsera, Inc. Prices Initial Public Offering at $18.00 per Share, Aiming for $275 Million Gross Proceeds
Metsera, Inc., a clinical-stage biotechnology company specializing in obesity treatments through injectable and oral hormone analog peptides, announced the pricing of its initial public offering ...
Metsera, Inc.: Metsera Announces Pricing of Initial Public Offering
Metsera, Inc. (Nasdaq: MTSR) ("Metsera"), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...